Here we tested rilmenidine, which previously showed the highest affinity for NISCH [68] To assess the differences in NISCH agonist effects between cancer types in which NISCH was a favorable and unfavorable prognostic marker, we chose two pancreatic cancer cell lines (MIA PaCa-2 and PANC-1) and two colon cancer cells lines (HCT 116 and HT-29). This evidence concerns the gene NISCH and malignant colon neoplasm.